Persons with HIV on combination antiretroviral therapy (cART) are at increased risk of the premature development of age-associated non-communicable comorbidities (AANCC). It has therefore been hypothesised that such individuals, despite the effective viral suppresion due to cART, may be prone to accelerated ageing. By building on an established infrastructure for conducting longitudinal HIV cohort studies in Amsterdam and London, the COBRA project provide a detailed, prospective evaluation of AANCC among HIV-infected patients suppressed on cART and appropriately chosen and comparible non-infected controls. The successful execution of the experimental and clinical research outlined in this study will be ensured through a strong interdisciplinary collaboration between clinical, basic and translational scientists bridging the fields of HIV, AANCC and ageing.
C3NL is part of the ComorBidity in Relation to AIDS (COBRA) collaboration, an EU-funded FP-7 project aimed at characterising the progressive brain changes associated with cART in older adulthood, lead by Prof Peter Reiss. The neuroimaging element of this project is being coordinated by Dr. James Cole and Prof. David Sharp of C3NL, in collaboration with researchers at the Academic Medical Centre (AMC) Amsterdam, principally Dr. Matthan Caan.